$46.23
0.04% day before yesterday
Nasdaq, May 02, 10:01 pm CET
ISIN
US85205L1070
Symbol
SWTX
Sector
Industry

SpringWorks Therapeutics Inc Stock price

$46.23
-0.29 0.62% 1M
+15.29 49.42% 6M
+10.10 27.95% YTD
+2.88 6.64% 1Y
+1.20 2.66% 3Y
+15.88 52.32% 5Y
+23.60 104.29% 10Y
Nasdaq, Closing price Fri, May 02 2025
+0.02 0.04%
ISIN
US85205L1070
Symbol
SWTX
Sector
Industry

Key metrics

Market capitalization $3.47b
Enterprise Value $3.17b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 16.54
P/S ratio (TTM) P/S ratio 18.10
P/B ratio (TTM) P/B ratio 7.15
Revenue growth (TTM) Revenue growth 3,417.33%
Revenue (TTM) Revenue $191.59m
EBIT (operating result TTM) EBIT $-278.13m
Free Cash Flow (TTM) Free Cash Flow $-180.05m
Cash position $307.99m
EPS (TTM) EPS $-3.48
P/E forward negative
P/S forward 10.11
EV/Sales forward 9.23
Short interest 12.69%
Show more

Is SpringWorks Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,786 stocks worldwide.

SpringWorks Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a SpringWorks Therapeutics Inc forecast:

6x Hold
100%

Analyst Opinions

6 Analysts have issued a SpringWorks Therapeutics Inc forecast:

Hold
100%

Financial data from SpringWorks Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
192 192
3,415% 3,415%
100%
- Direct Costs 16 16
390% 390%
8%
176 176
7,954% 7,954%
92%
- Selling and Administrative Expenses 250 250
30% 30%
130%
- Research and Development Expense 201 201
33% 33%
105%
-275 -275
19% 19%
-143%
- Depreciation and Amortization 3.47 3.47
22% 22%
2%
EBIT (Operating Income) EBIT -278 -278
19% 19%
-145%
Net Profit -258 -258
21% 21%
-135%

In millions USD.

Don't miss a Thing! We will send you all news about SpringWorks Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SpringWorks Therapeutics Inc Stock News

Neutral
Business Wire
4 days ago
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of SpringWorks Therapeutics, Inc. (NasdaqGS: SWTX) to Merck KGaA, Darmstadt, Germany. Under the terms of the proposed transaction, shareholders of SpringWorks will receive $47.00 in cash for each shar...
Neutral
PRNewsWire
5 days ago
NEW YORK , April 28, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) and its board of directors concerning the proposed acquisition of the company by Merck KGaA. Stockholders will receive $47.00 for each share of SpringWorks Therapeutics stock that they hold.
Neutral
Business Wire
6 days ago
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating SpringWorks (Nasdaq: SWTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, sha...
More SpringWorks Therapeutics Inc News

Company Profile

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in applying a precision medicine approach to acquiring, developing and commercializing medicines. It focuses on developing drugs for underserved patient populations suffering from devastating rare diseases and cancer. Its pipeline include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

Head office United States
CEO Saqib Islam
Employees 368
Founded 2017
Website www.springworkstx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today